In addition, melanoma patients who responded to ipilimumab had a higher proportion of FcγRIIIA+ CD16+ monocytes, suggesting that activated Fcγ receptors may serve as a potential predictor of response to therapy. This evidence concerns the gene FCGR3A and melanoma.